Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   30/04/2025
107,69 USD (+0,42%)
(+0,42%)   30/04/2025

30 april 2025 · Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia · Persbericht

24 april 2025 · Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry · Persbericht

14 april 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results · Persbericht

4 april 2025 · Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer · Persbericht

31 maart 2025 · Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia · Persbericht

20 maart 2025 · Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules · Persbericht

17 maart 2025 · Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules · Persbericht

11 maart 2025 · Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum · Persbericht

5 maart 2025 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults · Persbericht

12 september 2024 · Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia · Persbericht

10 september 2024 · Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference · Persbericht

28 augustus 2024 · Neurocrine Biosciences to Participate at Investor Conferences in September · Persbericht

28 augustus 2024 · Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia · Persbericht

7 augustus 2024 · Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference · Persbericht

1 augustus 2024 · Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance · Persbericht

18 juli 2024 · Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing · Persbericht

11 juli 2024 · Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results · Persbericht

1 juli 2024 · Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH · Persbericht

3 juni 2024 · Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 · Persbericht

3 juni 2024 · Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine · Persbericht

Mijn selecties